1,084 results on '"DE MARINIS, F."'
Search Results
302. Erlotinib Role in Pretreated Egfr Wild Type Caucasian Patients: A Retrospective Observational Study
303. Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)
304. Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial
305. Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC)
306. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
307. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study
308. 9147 POSTER Treatment and Clinical Outcomes of Young Patients (^40 Years) With Advanced Non-small Cell Lung (NSCLC) – Data From a Retrospective Multicentric Database
309. 9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results
310. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
311. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).
312. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.
313. Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC).
314. PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC).
315. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues
316. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
317. 4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC
318. 40IN WHAT IS MAINTENANCE? TERMS AND CONCEPTS
319. First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology.
320. Deacetylase inhibitor (DACI) panobinostat in relapsed small cell lung cancer (SCLC) patients: Results of a multicenter phase II trial.
321. Treatment and clinical outcome of young (age 40 and younger) patients with advanced non-small cell lung (NSCLC).
322. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force
323. 9034 Medical treatment choices of over 1000 Italian patients affected by stage IIIB-IV NSCLC in routine clinical practice: results from the observational "SUN" (Survey on the lUng cancer maNagement) study on behalf of SUN study Group
324. 9161 FLEX study: Prognostic factors in NSCLC
325. 9056 Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer (NSCLC)
326. Corrigendum to “Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting” [Crit. Rev. Oncol./Hematol. 66 (2008) 155–162]
327. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial.
328. P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial.
329. P1.16-04 Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors.
330. P14.07 PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC.
331. Activity and tolerability of Cisplatin (CDDP) and Fotemustine (FTM) combination in the treatment of patients with non-small cell lung cancer (NSCLC) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
332. EGFR mutations in patients with non-small cell lung cancer (NSCLC) and correlation with sensitivity to erlotinib
333. Induction chemotherapy followed by thoracic irradiation with or without concurrent chemotherapy in locally advanced inoperable NSCLC: A randomized phase III trial
334. Induction (Ind), gemcitabine (G), docetaxel (D) and cisplatin (C) plus concurrent (Con) chemotherapy with thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC)
335. Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator arms
336. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting
337. 1BA Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
338. Randomized phase II trial of two sequential schedules of docetaxel (D) and cisplatin (C) followed by gemcitabine (G) in patients with advanced non-small cell lung cancer
339. Stage III non small lung cancer (NSCLC): Docetaxel (D), gemcitabine (G), and cisplatin (C) as induction chemotherapy, an Italian phase I study
340. Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer
341. A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy
342. Second-line chemotherapy for non-small cell lung cancer
343. Locally advanced non-small cell lung cancer: role of induction chemotherapy in resectable N2 disease
344. Treatment of advanced non-small cell lung cancer
345. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy
346. Cisplatin, mytomicin, vindesine +/- lonidamine on the NSCLC chemotherapy at the stage 3 A-B inoperable
347. Consolidation chemotherapy with cisplatin and VP-16 after induction with a CEV regimen associated to radiotherapy on the SCLC treatment
348. Continuous infusion of metoclopramide plus desametazone in prevention of nausea and vomiting by cisplatin
349. P-830 Impact of chemotherapy (CT) related anemia onfunctional/cognitive capacity in elderly non-small cell lung cancer (NSCLC) patients
350. P-463 Preliminary results of a multicenter randomized phase II trial oftwo different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.